There are 3161 resources available
1068P - Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)
Presenter: Arielle Elkrief
Session: Poster session 04
1069TiP - A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies
Presenter: Manish Sharma
Session: Poster session 04
1070TiP - A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7
Presenter: Haiying Cheng
Session: Poster session 04
1071TiP - Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors
Presenter: Reinhard Dummer
Session: Poster session 04
1073TiP - A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors
Presenter: Tatiana Hernandez Guerrero
Session: Poster session 04
1074TiP - A phase I study of GIGA-564, a minimally blocking anti-CTLA-4 monoclonal antibody
Presenter: James Gulley
Session: Poster session 04
1075TiP - A phase I trial of ATG-101, an investigational PD-L1×4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN
Presenter: Junli Xue
Session: Poster session 04
Resources:
Abstract
1083P - KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
Presenter: Reinhard Dummer
Session: Poster session 04
1084P - Phase II study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma
Presenter: Muhammad Khattak
Session: Poster session 04